A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in New York City
-
Published:2020-10-05
Issue:4
Volume:96
Page:e575-e586
-
ISSN:0028-3878
-
Container-title:Neurology
-
language:en
-
Short-container-title:Neurology
Author:
Frontera Jennifer A.ORCID, Sabadia Sakinah, Lalchan Rebecca, Fang Taolin, Flusty Brent, Millar-Vernetti PatricioORCID, Snyder Thomas, Berger Stephen, Yang Dixon, Granger Andre, Morgan Nicole, Patel PalakORCID, Gutman Josef, Melmed KaraORCID, Agarwal Shashank, Bokhari Matthew, Andino Andres, Valdes EduardORCID, Omari Mirza, Kvernland Alexandra, Lillemoe Kaitlyn, Chou Sherry H.-Y., McNett Molly, Helbok Raimund, Mainali ShraddhaORCID, Fink Ericka L., Robertson Courtney, Schober Michelle, Suarez Jose I., Ziai Wendy, Menon David, Friedman Daniel, Friedman David, Holmes Manisha, Huang Joshua, Thawani Sujata, Howard Jonathan, Abou-Fayssal Nada, Krieger Penina, Lewis Ariane, Lord Aaron S.ORCID, Zhou Ting, Kahn D. Ethan, Czeisler Barry M.ORCID, Torres Jose, Yaghi Shadi, Ishida Koto, Scher Erica, de Havenon Adam, Placantonakis Dimitris, Liu Mengling, Wisniewski ThomasORCID, Troxel Andrea B., Balcer Laura, Galetta Steven
Abstract
ObjectiveTo determine the prevalence and associated mortality of well-defined neurologic diagnoses among patients with coronavirus disease 2019 (COVID-19), we prospectively followed hospitalized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–positive patients and recorded new neurologic disorders and hospital outcomes.MethodsWe conducted a prospective, multicenter, observational study of consecutive hospitalized adults in the New York City metropolitan area with laboratory-confirmed SARS-CoV-2 infection. The prevalence of new neurologic disorders (as diagnosed by a neurologist) was recorded and in-hospital mortality and discharge disposition were compared between patients with COVID-19 with and without neurologic disorders.ResultsOf 4,491 patients with COVID-19 hospitalized during the study timeframe, 606 (13.5%) developed a new neurologic disorder in a median of 2 days from COVID-19 symptom onset. The most common diagnoses were toxic/metabolic encephalopathy (6.8%), seizure (1.6%), stroke (1.9%), and hypoxic/ischemic injury (1.4%). No patient had meningitis/encephalitis or myelopathy/myelitis referable to SARS-CoV-2 infection and 18/18 CSF specimens were reverse transcriptase PCR negative for SARS-CoV-2. Patients with neurologic disorders were more often older, male, white, hypertensive, diabetic, intubated, and had higher sequential organ failure assessment (SOFA) scores (all p < 0.05). After adjusting for age, sex, SOFA scores, intubation, history, medical complications, medications, and comfort care status, patients with COVID-19 with neurologic disorders had increased risk of in-hospital mortality (hazard ratio [HR] 1.38, 95% confidence interval [CI] 1.17–1.62, p < 0.001) and decreased likelihood of discharge home (HR 0.72, 95% CI 0.63–0.85, p < 0.001).ConclusionsNeurologic disorders were detected in 13.5% of patients with COVID-19 and were associated with increased risk of in-hospital mortality and decreased likelihood of discharge home. Many observed neurologic disorders may be sequelae of severe systemic illness.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Neurology (clinical)
Cited by
249 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|